who we are

LS CancerDiag Ltd is a specialized in vitro diagnostics company committed to reducing cancer mortality rates with a low-cost, comprehensive method that detects the inherited cancer-causing condition prior to the development of cancer. The company has developed DiagMMR™, a functional diagnostic test for MMR deficiency, i.e. Lynch syndrome (LS). Established in 2013, LS CancerDiag is a spin-off from the University of Helsinki and is based on over 20 years of academic research.

Our solution

LS CancerDiag has created DiagMMR™, a unique non-invasive functional test to detect Lynch Syndrome from healthy subjects using a non-invasive tissue sample and without DNA testing or prior knowledge of family background. The groundbreaking DiagMMR™ method is a predictive diagnostic tool for easy screening of Lynch syndrome-related cancers. Whereas current screening methods only detect the cancer stage of the disease, the one-step DiagMMR™ method allows for accurate diagnosis before cancer has developed.

Benefits

Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer, HNPCC) is one of the main single causes of hereditary colorectal cancers; Lynch syndrome also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions of people with a severe risk of being affected by Lynch syndrome. The company’s mission is to save lives worldwide through an innovation that dramatically simplifies diagnosing Lynch syndrome, delivering accurate, predictive results using a fast and cost-efficient method.

what we are looking for

Our vision is to see the DiagMMR™ test as the new global standard in Lynch syndrome diagnostics. The test is now in the optimization phase with clinical validation starting in the first quarter of 2016 and commercialization targeted for the second half of 2017. LS CancerDiag is currently seeking business partners for licensing.

team profiles

PROFESSOR MINNA NYSTRÖM (PREV. NYSTRÖM­-LAHTI), PHD  
FOUNDER AND CHAIRMAN
Professor Nyström is the leading inventor of DiagMMR™  with more than 20 years of experience in the field of Lynch syndrome research. She has had an active role in both the identification of the LS related genes and mutations as well as the promoting the recognition of LS through over 50 scientific publications in the field. Prof. Nyström is an active member of the International Society for Gastrointestinal Hereditary Tumours, InSiGHT.
 
DR. MINTTU KANSIKAS, PHD
RESEARCH AND MARKETING DIRECTOR
Dr. Kansikas has worked on Lynch syndrome research in Prof. Nyström ́s lab for over 7 years and is a co-inventor of DiagMMR™. Her doctoral thesis, “Recognizing Lynch syndrome by DNA mismatch repair deficiency” focused on pathogenicity assessment and interpretation of LS associated mutations and functional detection of reduced mismatch repair.
 
DR. JUKKA KANTELINEN, PHD
RESEARCH AND DEVELOPMENT DIRECTOR
Dr. Kantelinen has worked on DNA mismatch repair research in Prof. Nyström ́s lab for over 9 years. His doctoral thesis, “Functional characterization of MutS homologue mismatch repair proteins and their variants” focused on functional characterization of LS mutations and the key molecular components of the MMR mechanism.
 
TUOMAS POSKIPARTA, MSC
COMMERCIAL DIRECTOR
As an equity partner, MSc Poskiparta brings vast experience of running multiple startup companies as well as large scale business operations. He is also responsible for the commercialization of DiagMMR™.

Contact information

Tuomas Poskiparta

tuomas(a)poskiparta.com

www.lscancerdiag.com

Viikinkaari 9 C, 00790 Helsinki, FINLAND


Related posts